On August 27, 2026, H.C. Wainwright analyst Mitchell S. Kapoor initiated coverage of Ascendis Pharma with a Buy rating and a $345 price target. Ascendis Pharma is a Denmark-based biopharmaceutical company developing and commercializing therapies for endocrinology-related rare diseases.
Ascendis Pharma closed at $250.25 on August 26, the trading day before H.C. Wainwright’s initiation. Based on that reference price, the $345 target represented potential upside of approximately 37.9%. Analyst price targets reflect the analyst’s expectations and assumptions, but they do not guarantee that a stock will reach the projected value.
Other recent analyst actions include BMO Capital Markets initiating coverage with an Outperform rating and a $319 target, RBC Capital raising its target to $290, and Wedbush maintaining an Outperform rating with a $327 target.
Ascendis Pharma also announced an important legal and commercial development involving BioMarin. On August 30, 2026, the companies entered into a binding term sheet setting out the terms of a planned global settlement and license agreement covering YUVIWEL, also known as navepegritide or TransCon CNP.
Under the proposed agreement, BioMarin will grant Ascendis a non-exclusive, worldwide license to certain patents covering the research, development, manufacturing, and commercialization of YUVIWEL and related products. The agreement is intended to resolve pending legal proceedings involving those patent rights. However, the announcement concerned a binding term sheet, and the companies still anticipated entering into a more detailed settlement and license agreement.
The agreement reduces some patent-related uncertainty but also creates a significant financial obligation for Ascendis. The company will pay BioMarin royalties equal to 20% of annual net sales in the United States and 18% of annual net sales in the European Union, Brazil, and South Korea. These royalties will apply from the first commercial sale in each territory, retroactively where applicable, through May 2030.
Ascendis Pharma also presented Week 104 results from the pivotal ApproaCH trial at the International Skeletal Dysplasia Society’s 2026 annual meeting on August 28. The study evaluated once-weekly TransCon CNP in children between two and 11 years old with achondroplasia.
According to Ascendis, children treated with TransCon CNP demonstrated durable improvements in height, lower-limb alignment, body proportionality, and physical functioning through 104 weeks. Children who switched from placebo to TransCon CNP after Week 52 also showed meaningful improvements. The treatment was generally well tolerated, with most adverse events classified as mild or moderate and no adverse events leading to treatment discontinuation.
TransCon CNP is no longer solely a development-stage pipeline product. In February 2026, the U.S. Food and Drug Administration approved it under the brand name YUVIWEL to increase linear growth in pediatric patients aged two years and older with achondroplasia and open growth plates. The Week 104 results therefore provide longer-term supporting evidence for an already approved therapy.
Ascendis Pharma closed at $247.91 on August 28, 2026. Following the BioMarin announcement, the shares traded around $267 during the morning of August 31, implying a market capitalization of approximately $16.5 billion. At $267, H.C. Wainwright’s $345 target would represent potential upside of approximately 29.2%.
Over the preceding 52 weeks, Ascendis Pharma shares traded between approximately $186.05 and $282.15. Although analyst ratings, the BioMarin agreement, and the Week 104 data support a positive commercial outlook, investors should also consider the royalty burden, commercialization risks, competition, regulatory developments outside the United States, and the volatility typically associated with biotechnology stocks.
